Financials data is unavailable for this security.
View more
Year on year OSE Immunotherapeutics SA 's revenues fell -87.83% from 18.30m to 2.23m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 17.76m to a larger loss of 23.00m.
Gross margin | -- |
---|---|
Net profit margin | -1,032.87% |
Operating margin | -1,032.15% |
Return on assets | -26.46% |
---|---|
Return on equity | -82.70% |
Return on investment | -33.15% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at OSE Immunotherapeutics SA fell by 6.95m. Cash Flow from Financing totalled 13.32m or 598.29% of revenues. In addition the company used 19.77m for operations while cash used for investing totalled 507.00k.
Cash flow per share | -0.9777 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.06 |
---|---|
Tangible book value per share | -1.09 |
More ▼
Balance sheet in EURView more
Current ratio | 1.62 |
---|---|
Quick ratio | -- |
Total debt/total equity | 1.99 |
---|---|
Total debt/total capital | 0.6659 |
More ▼